Total submissions: 1
| Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
|---|---|---|---|---|---|---|---|---|
| Victorian Clinical Genetics Services, |
RCV003225636 | SCV003921838 | pathogenic | Focal segmental glomerulosclerosis 1 | 2022-02-02 | criteria provided, single submitter | clinical testing | Based on the classification scheme VCGS_Germline_v1.3.4, this variant is classified as Pathogenic. Following criteria are met: 0103 - Dominant negative and gain of function are suggested mechanisms of disease in this gene and are associated with glomerulosclerosis, focal segmental, 1, (MIM#603278). Functional analysis of missense variants within the binding domain demonstrates they result in both increased actin binding, and impaired wildtype protein localization with downstream consequences such as protein aggregates and inability to stimulate nuclear transcription. Loss of function is also a potential mechanism of disease for variants within the LXXLL motif (PMID: 10700177, PMID: 22351778, PMID: 26740551, PMID: 26301083). (I) 0107 - This gene is associated with autosomal dominant disease. (I) 0200 - Variant is predicted to result in a missense amino acid change from glycine to valine. (I) 0251 - This variant is heterozygous. (I) 0301 - Variant is absent from gnomAD (both v2 and v3). (SP) 0501 - Missense variant consistently predicted to be damaging by multiple in silico tools or highly conserved with a major amino acid change. (SP) 0603 - Missense variant in a region that is highly intolerant to missense variation (high constraint region in DECIPHER). (SP) 0704 - Another missense variant comparable to the one identified in this case has limited previous evidence for pathogenicity. This alternative change (p.(Gly195Asp)) has been reported as de novo in an individual with focal segmental glomerulosclerosis (PMID: 26740551). (SP) 0807 - This variant has no previous evidence of pathogenicity. (I) 0905 - No published segregation evidence has been identified for this variant. (I) 1007 - No published functional evidence has been identified for this variant. (I) 1203 - This variant has been shown to be de novo in the proband (parental status confirmed, by trio analysis). (SP) Legend: (SP) - Supporting pathogenic, (I) - Information, (SB) - Supporting benign |